Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns. With Elevidys generating 43% of Sarepta's total revenues and holding traditional approval since June 2024 for ambulatory patients, any regulatory challenge poses existential threats to the company.
FDA Commissioner Marty Makary's statement that he's "taking a hard look" at whether Elevidys should remain on the market suggests potential forced withdrawal if voluntary compliance fails. The recent $400 million restructuring cost savings appear insufficient against potential revenue loss from broader market restrictions.
Sarepta's confrontational approach toward federal regulators is creating unprecedented uncertainty, even for biotech investors who typically have a high tolerance for risk. This unwillingness to proactively address safety concerns demonstrates poor risk management, especially at a time when regulatory goodwill is crucial. Situations like this underscore our consistent message about the inherent risks of investing in single stocks and highlight why professionally managed portfolios are often a better choice.
In fact, regulatory risk is just a small part of the risk assessment framework we apply while constructing the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Korea Pitches Trump on Shipyards for Last-Minute Trade Deal
South Korea is pitching the US on a shipbuilding partnership as a key proposal to seal a last-minute agreement to avoid a 25% tariff rate. While details remain unclear, Yonhap News reported that South Korea has proposed a multi-billion dollar project dubbed 'Make American Shipbuilding Great Again.' South Korea's Industry Ministry declined to comment.
Yahoo
2 hours ago
- Yahoo
Where Does Trader Joe's Source Its Eggs From?
Trader Joe's, a beloved grocery chain known for its private label products, offers a wide assortment of eggs. Its selection features Grade A eggs in various sizes and standards, such as farm fresh eggs (which are one of the secrets for making the best scrambled eggs), pasture-raised eggs, and cage-free eggs. But who is housing the hens that produce them? While Trader Joe's keeps its prices cheap by selling only its own private labels, many of the eggs offered at the chain are sourced from Carol's Eggs, a brand that falls under the umbrella of the New Hampshire-based company Pete & Gerry's. When companies use private labels, such as Carol's Eggs, there is often no interaction with the farmers, which can obscure farming practices. However, those worried about the treatment of the hens at Carol's Eggs will be happy to hear that the operation is fully transparent and meets humane standards when it comes to raising chickens. In fact, the non-profit watchdog organization The Cornucopia Institute noted that the farm allowed its hens access to a well-vegetated pasture and both indoor and outdoor enrichment. Although there are some items you should never buy at Trader Joe's, you can rest assured that TJ's eggs are high quality. Moreover, Carol's Eggs' parent company, Pete & Gerry's, paved the way for humane and sustainable egg production in the U.S. Read more: The Definitive Ranking Of Grocery Store Butter Brands The History Of Pete & Gerry's Carol's Eggs, along with the overarching Pete & Gerry's brand, originated from the Ward family farm in the 1950s. Les Ward passed the farm down to his daughter, Carol Ward, and her husband, Gerry Laflamme. Later, the married couple joined with Carol's cousin Pete to create the parent company Pete & Gerry's in 1980. However, the merger between the two happened during the farming crisis that spanned throughout the '70s and into the mid 1980s. The crisis was driven in part by poor lending policies that left many small-town farms in financial ruin. As a result, the industry saw widespread consolidation and the rise of factory farming. For Pete & Gerry's, this meant an uphill battle to compete against industrial-sized egg producers and the company fell on hard times as a result. Despite the challenges, the egg producer did not adopt industrialized farming methods. Around this time, however, Carol and Gerry's son, Jesse Laflamme, had returned home from college to take over the family business full-time. Jesse made the bold decision to go fully organic, telling Inc. in a 2018 interview that the change was a "Hail Mary pass to save the farm, since the organic market was practically nonexistent at the time." Despite the risk, his plan paid off, and the farm turned around within two years. In 2003, Pete & Gerry's became the first egg producer in the United States to become Certified Humane. Read the original article on Chowhound. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Tariff Noise Receding Into the Background for Markets, Rainwater Equity CEO Says
Rainwater Equity Founder and CEO Joseph Shaposhnik says he views "the S&P 500 in the US as the great growth stock of all countries today." He tells Bloomberg Television that President Trump's ongoing trade deals will "be positive" for US stocks as they lessen "the uncertainty that has faced the markets for the last six months." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
